The Uterine Cancer Therapeutics Market size in the Middle East & Africa is expected to reach USD 1.03 Billion by 2027 from USD 0.79 Billion in 2020, growing at a CAGR of 5.40% during the forecast period.
The Uterine Cancer Therapeutics Market in the MEA region is expected to be driven by the rising number of uterine cancer population, growing awareness among people about uterine therapies, and increasing demand for advanced therapies are driving the market growth. In addition, an increase in cases of women being diagnosed with uterine cancer across the region is influencing the market growth. Furthermore, increasing risk factors leading to cancer is one of the major factors driving the market growth. In addition, the rising importance of targeted diseases is also surging the market growth.
Moreover, technological advancements in uterine cancer therapeutics provide lucrative opportunities for the market players to introduce new products. In addition, increasing investment and funding by the government and private organizations to develop novel drugs to treat cancer is expanding the market growth.
In addition, increasing healthcare expenditure, growing advancements in cancer screening & treatment methods, and the rising focus of government to provide adequate healthcare services are augmenting the market growth.
In South Africa, the Cancer Association of South Africa (CANSA) is an organization that offers integrated services to the people affected by cancer in the country. Its purpose includes conducting cancer-prevention research, educating the public about symptoms, screening and risk reduction, and providing treatment and support to all cancer patients. In addition, the South African Department of Health launched initiatives to promote women's health, and all of these programs are projected to boost early diagnosis procedures in the near future.
However, the low success rate of cancer drug clinical trials, expensive treatment techniques, terrible side effects, and high toxicity of these drugs are all expected to restricting the MEA regional market growth in uterine cancer therapy and diagnosis.
This research report on the MEA Uterine Cancer Therapeutics Market is segmented & sub-segmented into the following categories:
The MEA Uterine Cancer Therapeutics Market is projected to witness a promising share during the forecast period due to the increasing incidence of diseases and a growing number of women diagnosed with uterine cancer in the region. Developing countries such as Saudi Arabia, South Africa, and UAE contribute to the development of regional cancer centers. Over the forecast period, South Africa and UEA accounted significant share in the Uterine cancer therapeutics market. Increasing obesity among women is thought to be the primary cause of the rise in endometrial cancer cases. With the rising prevalence of the condition and increased awareness of it, it is expected that the segment will develop rapidly in the near future.
According to the National Clinical Trials (NCT) Registry, the "ASPIRE" clinical study for the treatment of endometrial cancer with stereotactic ablative radiation (SABR/SBRT) therapy is in phase II development in Saudi Arabia as of June 18, 2020. If the study results in a favorable conclusion, the market will be boosted in the near future since new therapies are planned in the coming years. Therefore, due to these activities and research efforts, the region's market is projected to grow in the future.
KEY MARKET PLAYERS:
A few of the prominent companies operating in the MEA Uterine Cancer Therapeutics market profiled in this report are Abbott Laboratories, Ariad Pharmaceuticals, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co., Inc., Novartis AG, Sanofi, Siemens Healthcare GmbH and Takeda Pharmaceutical Company Ltd.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org